Appetite Suppression by GLP ‐1 Receptor Agonists: Role of Delayed Gastric Emptying
Obesity · 2026
DOI: 10.1002/oby.70255 ↗At a glance
Randomisierte kontrollierte Studie in Obesity, 2026. Written by Mark I Friedman and 2 co-authors. Institution: Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Gastric Emptying, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Cited 4 times so far (Crossref); 16 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIDDK NIH HHS, NIH HHS, National Institutes of Health.
Abstract (original language)
Objective
This study aimed to evaluate relationships between delayed gastric emptying and appetite suppression during treatment with liraglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA).
Methods
We conducted a secondary data analysis from a 16‐week randomized, placebo‐controlled liraglutide trial in patients with obesity. We examined correlations between solid food gastric emptying and measurements of satiation and energy intake in the entire cohorts at baseline and end of treatment and separately in placebo‐ and liraglutide‐treated patients who completed the trial. We also compared appetitive measures among liraglutide‐treated participants who displayed either normal, persistently delayed, or transiently delayed emptying during treatment.
Results
In the entire cohorts at baseline and completion, gastric emptying correlated significantly with energy intake and, at baseline, with one parameter of satiation. Gastric emptying accounted for only 4%–6% of the variance in these appetitive measures. No such correlations were found in the placebo‐ or liraglutide‐treated groups alone. There were no differences in appetitive measures among the subgroups that displayed different gastric emptying patterns during liraglutide treatment.
Conclusions
Delayed gastric emptying appears to play little direct role in appetite suppression induced by liraglutide. Further research should explore whether delayed emptying or other gastrointestinal effects of other GLP‐1RAs affect appetite directly or indirectly. Trial Registration: ClinicalTrials.gov identifier: NCT02647944
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA.
- CENTER Program, Mayo Clinic, Rochester, Minnesota, USA.
ORCID profiles: Mark I Friedman, Michael Camilleri
Funding
- NIDDK NIH HHS
- NIH HHS
- National Institutes of Health
Cite
APA
Friedman, M. I., Harmsen, W. S., & Camilleri, M. (2026). Appetite Suppression by GLP ‐1 Receptor Agonists: Role of Delayed Gastric Emptying. Obesity. https://doi.org/10.1002/oby.70255
Vancouver
Friedman MI, Harmsen WS, Camilleri M. Appetite Suppression by GLP ‐1 Receptor Agonists: Role of Delayed Gastric Emptying. Obesity. 2026. doi:10.1002/oby.70255
BibTeX
@article{Friedman2026,
author = {Friedman, Mark I and Harmsen, W Scott and Camilleri, Michael},
title = {Appetite Suppression by GLP ‐1 Receptor Agonists: Role of Delayed Gastric Emptying},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70255}
}
EUVIMED